437 / 1778
NCT01561586: A Phase III Randomized Trial
Korean GOG study
Stage : 1B2 - IVA
Estimated sample: 590
Actual Study Start Date : March
2012Estimated Primary Completion Date : March
2020Estimated Study Completion Date : March
2023•
Primary end-point :
Overall survival
•
Secondary end-points:
PFS, Toxicity,
Compliance to radiation protocol, QOL.